Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: CASI pharmaceuticals, Inc. Clear all
Completed Phase 2 Interventional

Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00568646
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MKC-1
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)

NCT00481455
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
Panzem NCD, Temozolomide
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2008 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer

NCT00408226
View directory record Official record
Conditions
Advanced Cancer, Non-Small Cell Lung Cancer
Interventions
MKC-1, pemetrexed
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1

NCT00306631
View directory record Official record
Conditions
Breast Cancer
Interventions
MKC-1
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

NCT02234986
View directory record Official record
Conditions
Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma
Interventions
ENMD-2076
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

Study of ENMD-2076 in Patients With Multiple Myeloma

NCT00806065
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ENMD-2076
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

NCT00658671
View directory record Official record
Conditions
Advanced Cancer
Interventions
ENMD-2076
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

NCT01104675
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Cancer, Peritoneal Cancer
Interventions
ENMD-2076
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

NCT00328497
View directory record Official record
Conditions
Carcinoid Tumor
Interventions
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer

NCT00400348
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Panzem Nanocrystal Colloidal Dispersion (NCD)
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 25, 2008 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma

NCT00592579
View directory record Official record
Conditions
Relapsed Multiple Myeloma, Plateau Phase Multiple Myeloma
Interventions
2-methoxyestradiol
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2009 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

NCT00444314
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Panzem® NCD, Sunitinib Malate
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

NCT00394810
View directory record Official record
Conditions
Prostate Cancer
Interventions
Panzem® NCD
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2008 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of MKC-1 in Patients With Advanced Cancer

NCT00656461
View directory record Official record
Conditions
Advanced Cancer
Interventions
MKC-1
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

NCT01639248
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
ENMD-2076
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer

NCT00049790
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
recombinant human Angiostatin protein, paclitaxel, carboplatin
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 9, 2009 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma

NCT00306618
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
Panzem Nanocrystal Colloidal Dispersion
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2008 · Synced Oct 1, 2026, 7:14 PM EDT